Study of the effect of selective inhibitor of Arginase II KUD 975 and of low doses of Acetylsalicylic acid on the functional parameters of the cardiovascular system In experimental preeclampsia

@inproceedings{Severinova2019StudyOT,
  title={Study of the effect of selective inhibitor of Arginase II KUD 975 and of low doses of Acetylsalicylic acid on the functional parameters of the cardiovascular system In experimental preeclampsia},
  author={Olga V. Severinova and Vladimir V. Gureev and Lyudmila A. Zhilinkova and Galina A. Lazareva and Anastasia V. Gureeva and Sofia S. Lazareva},
  year={2019}
}
Introduction: Over the past decade, preeclampsia has been the subject of an increased attention, as this complication is the most common cause of maternal mortality, triggering every third case of obstetric morbidity and taking lives of up to 50.000 young women worldwide each year. Despite a large number of ongoing studies, no clear algorithm for monitoring pregnant women with this pathology has been developed yet. Materials and methods: The study was conducted on 220 female Wistar rats… 

Figures and Tables from this paper

Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia
TLDR
Arginase II selective inhibitors K UD-259 and KUD-974 and asialized erythropoietin have a pronounced positive effect on the correction of morphofunctional disorders in animals with ADMA-like preeclampsia.
Erythropoietin Mimetic Peptide (pHBSP) Corrects Endothelial Dysfunction in a Rat Model of Preeclampsia
TLDR
The administration of short-chain peptides mimicking the spatial structure of the B erythropoietin chain may become one of the directions of searching for new drugs for preeclampsia prevention and therapy.
INFLUENCE OF PEPTIDE IMITATING α-SPIRAL OF B ERYTHROPOETHIN ON THE DEVELOPMENT OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PRECLAMPPS
Преэклампсия остается грозным заболеванием второй половины беременности. Поэтому поиск новых лекарственных препаратов для лечения и профилактики преэклампсии – актуальная задача современной

References

SHOWING 1-10 OF 40 REFERENCES
Correction of adma-induced preeclampsia with the use of phosphodiesterase 5 and selective inhibitor of arginase II zb49-0010
TLDR
Simulation experimental ADMA-like preeclampsia was carried out by administering the rats with L-NAME during 14-20 days of pregnancy and the use of phosphodiesterase 5 and selective inhibitor of arginase II ZB49-0010 leads to the expression of morphological and functional correction of violations occurring in modeling of experimental preeclamping.
Change of indicators of a hemostasis at females with experimental gestosis under the influence of gaba derivatives
TLDR
Anticoagulant and antiplatelet activity in the conditions of experimental gestosis are shown, extending APTT, thrombin and a prothrombin time, reducing fibrinogen level, reducing platelet aggregation.
The impact of platelet functions and inflammatory status on the severity of preeclampsia
  • S. Sahin, O. Ozakpinar, Ş. Tetik
  • Medicine, Biology
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2015
TLDR
The severity of inflammation is found to be independent from the intensity of platelet activation in preeclamptic women, and seems to be related to mechanisms causing alterations of cytokine levels such as IL-8 and IL-10, rather than plateletactivation.
Vasoprotection by nitric oxide: mechanisms and therapeutic potential.
[Correction of endothelial dysfunction by L-arginine under experimental pre-eclampsia conditions].
The ADMA-like pre-eclampsia in pregnant rats was modeled by daily introduction of L-NAME in a dose of 25 mg/kg for 7 days. L-arginine (200 mg/kg) prevented the development of arterial hypertension
APPROACHES TO CORRECTION OF ISCHEMIC AND REPERFUSION KIDNEY INJURIES IN EXPERIMENT
Background: Acute kidney injury is an urgent health problem at the junction of specialties with a high level of disability and mortality of patients. The pertinence of the study stems from
The effects of sustained-release-L-arginine formulation on blood pressure and vascular compliance in 29 healthy individuals.
  • A. Miller
  • Medicine
    Alternative medicine review : a journal of clinical therapeutic
  • 2006
TLDR
This study demonstrates blood pressure reductions, especially in patients with borderline or frank hypertension, as well as improved vascular compliance - an indicator of improved endothelial function and perfusion - after a one-week trial of sustained-release L-arginine.
[Systemic production of cytokines and growth factors in various forms of syndrome of delayed fetal growth].
TLDR
Revealing of immunoregulation disorders on systemic and local levels would promote the creation of a concept, depicting participation of the immune system in formation of asymmetrical and symmetrical forms of SDFG, to elaborate new approaches for prognosis and diagnosis.
Use of L-arginine immobilised on activated carbon for pharmacological correction of endothelial disfunction
TLDR
In animal experiments it was shown that granulirovannye the form of a combined preparation exhibits a pronounced anti-hypertensive, endothelioprotecive and cardioprotective activity in a dosage of 200 mg/kg.
Pharmacological Correction of Endothelial Dysfunction in Rats using e-NOS Cofactors.
TLDR
The combined use of e-NOS cofactors shown positive pharmacodynamic interaction and increase the effectiveness of therapy compared to administration of the individual compounds.
...
1
2
3
4
...